US OptionsDetailed Quotes
CGEN250117P2500
- 0.95
- 0.000.00%
15min DelayClose Jan 10 16:00 ET
0.00High0.00Low
0.95Open0.95Pre Close0 Volume49 Open Interest2.50Strike Price0.00Turnover216.58%IV5.49%PremiumJan 17, 2025Expiry Date0.86Intrinsic Value100Multiplier6DDays to Expiry0.09Extrinsic Value100Contract SizeAmericanOptions Type-0.9139Delta0.3463Gamma1.87Leverage Ratio-0.0053Theta-0.0003Rho-1.71Eff Leverage0.0003Vega
Compugen Stock Discussion
Sign in to post a comment
$Compugen (CGEN.US)$
Compugen Announces First Patient Dosed in Phase 1 Clinical Trial to Evaluate COM503 as Monotherapy and in Combination with Zimberelimab in Advanced Solid Tumors
Wednesday, 8th January at 7:00 am
• New approach to harness cytokine biology to treat cancer patients advances to the clinic
• First patient dosed with potential first-in-class anti-IL-18 binding protein antibody, COM503, licensed to Gilead Sciences, Inc.
• Phase 1 dose escalation and dose expansion trial...
Compugen Announces First Patient Dosed in Phase 1 Clinical Trial to Evaluate COM503 as Monotherapy and in Combination with Zimberelimab in Advanced Solid Tumors
Wednesday, 8th January at 7:00 am
• New approach to harness cytokine biology to treat cancer patients advances to the clinic
• First patient dosed with potential first-in-class anti-IL-18 binding protein antibody, COM503, licensed to Gilead Sciences, Inc.
• Phase 1 dose escalation and dose expansion trial...
4
$ABVC BioPharma (ABVC.US)$ - Progress continues in our ADHD program with Phase IIb trials at multiple prominent sites. We aim to have an interim report by Q4 2024. ABV-1601 for MDD in cancer patients has completed Phase I study preparation, including the Site Initiation Visit (SIV). The study is set to initiate by the end of 2024.
$Ascent Solar Technologies (ASTI.US)$- Following delivery and the successful completion of the on-orbi...
$Ascent Solar Technologies (ASTI.US)$- Following delivery and the successful completion of the on-orbi...
28
9
7
$Compugen (CGEN.US)$
Compugen Expands its Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use of COM902 (reduced Fc anti-TIGIT) with anti-PD-1 and anti-PVRIG Antibodies
Compugen (NASDAQ: CGEN) has been granted a new U.S. patent (No. 12152084) covering the triple combination use of its COM902 anti-TIGIT antibody with anti-PD-1 and anti-PVRIG antibodies for cancer treatment.
The patent strengthens Compugen's IP portfolio and protects the use of COM902, a reduc...
Compugen Expands its Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use of COM902 (reduced Fc anti-TIGIT) with anti-PD-1 and anti-PVRIG Antibodies
Compugen (NASDAQ: CGEN) has been granted a new U.S. patent (No. 12152084) covering the triple combination use of its COM902 anti-TIGIT antibody with anti-PD-1 and anti-PVRIG antibodies for cancer treatment.
The patent strengthens Compugen's IP portfolio and protects the use of COM902, a reduc...
1
$Compugen (CGEN.US)$ 🤩
Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig
Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig
The market anticipates a decline in future revenue, possibly explaining the suppressed P/S. This weak revenue outlook could continue to pressure shares, making it hard to maintain current prices. Shareholders accept the low P/S, expecting future revenue may not bring pleasant surprises.
Michelle Mahler's appointment as Chief Medical Officer is a positive step for Compugen, thanks to her vast clinical development experience. Her leadership in the COM503 Phase 1 study and future role in advancing COM701, COM902, and COM503 are anticipated to significantly boost the company's clinical development strategy.
$Compugen (CGEN.US)$ can go up today?
$Compugen (CGEN.US)$ come on get up there so I can sell some calls lol
7
’s close now or forever hold your peace!!
$Compugen (CGEN.US)$ this stock can move up , dont worry
1
4
$Compugen (CGEN.US)$ today 3-4buck!
1
1
No comment yet
Ezkilz : no news is moving any share?
Jaguar8 OP Ezkilz : It’s a red day because of the Fed report
Ezkilz Jaguar8 OP : ok i got some jspr, how do i check cash on hand?
Jaguar8 OP Ezkilz : Dilution tracker